加载中...

MedXY AI/MedXY News/Tag: cardiovascular risk

MedXY News

EnglishTag

cardiovascular risk

75 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Genetic Liability to Hypertensive Disorders of Pregnancy Predicts Increased Long‑Term Cardiovascular Risk: Mendelian Randomization and Polygenic Risk Evidence

Genetic Liability to Hypertensive Disorders of Pregnancy Predicts Increased Long‑Term Cardiovascular Risk: Mendelian Randomization and Polygenic Risk Evidence

Genetic predisposition to preeclampsia and gestational hypertension is associated with higher risk of later-life cardiovascular disease; polygenic risk amplifies this risk, while obstetric history improves risk stratification beyond PRSs al

Section: CardiologyNov 29, 2025

Gender‑Affirming Hormone Therapy and Acute Cardiovascular Events: Dutch Cohort Finds Lower MI but Higher VTE in Transgender Women, Elevated MI and Stroke Risk in Transgender Men

Gender‑Affirming Hormone Therapy and Acute Cardiovascular Events: Dutch Cohort Finds Lower MI but Higher VTE in Transgender Women, Elevated MI and Stroke Risk in Transgender Men

A large Dutch cohort study found that after adjusting for socioeconomic status and lifestyle, transgender women on oestradiol had lower myocardial infarction (MI) risk but higher venous thromboembolism (VTE) risk; transgender men on testost

Section: CardiologyNov 29, 2025

Invisible Invaders: How Microplastics May Accelerate Atherosclerosis — and Why Men Could Be at Greater Risk

Invisible Invaders: How Microplastics May Accelerate Atherosclerosis — and Why Men Could Be at Greater Risk

New animal research links oral microplastic exposure to dramatic increases in arterial plaque—especially in males—by injuring endothelial cells and provoking inflammation and oxidative stress.

Section: CardiologyNov 25, 2025

Global CKD Now Affects 788 Million Adults (1990–2023): Rising Prevalence, Growing Mortality, and a Major Cardiovascular Risk

Global CKD Now Affects 788 Million Adults (1990–2023): Rising Prevalence, Growing Mortality, and a Major Cardiovascular Risk

The GBD 2023 analysis estimates 788 million adults living with chronic kidney disease in 2023, rising since 1990, with CKD a top-10 cause of death and a major contributor to cardiovascular mortality. Urgent action on screening, prevention,

Section: NephrologyNov 11, 2025

Even a Few Days of 4,000+ Steps Lowers Mortality and CVD Risk in Older Women — More Steps Still Better

Even a Few Days of 4,000+ Steps Lowers Mortality and CVD Risk in Older Women — More Steps Still Better

In >13,000 older women followed ≈11 years, achieving ≥4,000 steps on as little as 1–2 days/week was linked to lower all‑cause mortality and CVD; higher daily step thresholds produced additional benefit, but associations were driven largely

Section: CardiologyNov 4, 2025

Aspirin Use in Chronic Coronary Syndrome Patients on Oral Anticoagulation: Balancing Risks and Benefits

Aspirin Use in Chronic Coronary Syndrome Patients on Oral Anticoagulation: Balancing Risks and Benefits

A randomized trial revealed that adding aspirin to oral anticoagulation in chronic coronary syndrome patients increases adverse cardiovascular events, mortality, and major bleeding, challenging conventional dual therapy approaches.

Section: CardiologyOct 31, 2025

Impact of Diabetes on the Triglyceride-Glucose Index and Cardiovascular Outcomes in Coronary Heart Disease: A Comprehensive Meta-Analysis

Impact of Diabetes on the Triglyceride-Glucose Index and Cardiovascular Outcomes in Coronary Heart Disease: A Comprehensive Meta-Analysis

This meta-analysis of 36 cohort studies shows that higher triglyceride-glucose index levels predict increased risk of major adverse cardiovascular events in coronary heart disease patients, with differential effects observed by diabetes sta

Section: CardiologyOct 20, 2025

Comparing the PREVENT and PCE Models for 10-Year ASCVD Risk Prediction: Insights from a Large Real-World Cohort

Comparing the PREVENT and PCE Models for 10-Year ASCVD Risk Prediction: Insights from a Large Real-World Cohort

This review evaluates PREVENT versus PCE models for estimating 10-year ASCVD risk focusing on accuracy in patients with and without statin therapy, highlighting implications for personalized prevention.

Section: CardiologyOct 9, 2025

Long-Term Outcomes of the DASH Intervention in Nonobstructive Coronary Artery Disease: Follow-Up of the DISCO-CT Study

Long-Term Outcomes of the DASH Intervention in Nonobstructive Coronary Artery Disease: Follow-Up of the DISCO-CT Study

A one-year DASH diet intervention led to sustained suppression of proatherogenic chemokine CXCL4 and fewer major cardiovascular events over six years despite reduced adherence and partial loss of initial benefits in nonobstructive CAD patie

Section: CardiologyOct 8, 2025

The Hidden Vascular Assassin: How Homocysteine Independently Accelerates Atherosclerosis

The Hidden Vascular Assassin: How Homocysteine Independently Accelerates Atherosclerosis

Beyond cholesterol and blood pressure, homocysteine silently hardens arteries, driving cardiovascular disease progression independently—latest research reveals its biomechanical impact and prevention strategies.

Section: Medical NewsSep 14, 2025

CT Angiography Enhances Lifestyle and Prevention Uptake in Cardiovascular Risk Management: Insights from SCOT-HEART 2 Substudy

CT Angiography Enhances Lifestyle and Prevention Uptake in Cardiovascular Risk Management: Insights from SCOT-HEART 2 Substudy

A nested substudy from SCOT-HEART 2 reveals coronary CT angiography modestly improves healthy lifestyle adherence, preventive therapy acceptance, and risk factor modification compared to traditional cardiovascular risk scoring in asymptomat

Section: CardiologyOct 8, 2025

Preoperative Cardiovascular Risk Does Not Alter Outcomes of Renin-Angiotensin System Inhibitor Use Before Major Noncardiac Surgery: Insights from a Secondary Analysis of the STOP-or-NOT Trial

Preoperative Cardiovascular Risk Does Not Alter Outcomes of Renin-Angiotensin System Inhibitor Use Before Major Noncardiac Surgery: Insights from a Secondary Analysis of the STOP-or-NOT Trial

A secondary analysis of the STOP-or-NOT trial shows that preoperative cardiovascular risk stratification does not impact postoperative outcomes related to continuing or discontinuing renin-angiotensin system inhibitors before major noncardi

Section: CardiologyOct 8, 2025

Mobile Text Messaging Enhances Glycemic and Blood Pressure Control in Adults with Uncontrolled Type 2 Diabetes

Mobile Text Messaging Enhances Glycemic and Blood Pressure Control in Adults with Uncontrolled Type 2 Diabetes

A randomized trial in China shows that a 12-month mobile message-based intervention modestly improves HbA1c and systolic blood pressure in patients with uncontrolled type 2 diabetes, supporting mHealth strategies to manage cardiovascular ri

Section: CardiologyOct 8, 2025

Obicetrapib: A Promising Advance in LDL Cholesterol Lowering for High Cardiovascular Risk Patients

Obicetrapib: A Promising Advance in LDL Cholesterol Lowering for High Cardiovascular Risk Patients

Obicetrapib significantly reduces LDL cholesterol by nearly 30% in high-risk cardiovascular patients on maximal lipid therapy, with a safety profile comparable to placebo, representing a potential novel agent in managing familial hyperchole

Section: CardiologyOct 7, 2025

Interleukin-17 Inhibitors and Cardiovascular Risk: Evaluating Early Major Adverse Cardiovascular Events

Interleukin-17 Inhibitors and Cardiovascular Risk: Evaluating Early Major Adverse Cardiovascular Events

A national database study finds no significant increase in early major adverse cardiovascular events (MACEs) after starting IL-17 inhibitors in psoriasis and related diseases, although a modest risk cannot be excluded.

Section: Allergy & ImmunologyOct 7, 2025

Lower High Blood Lipids Risk: Avoid Common Pitfalls and Embrace 4 Healthy Habits

Lower High Blood Lipids Risk: Avoid Common Pitfalls and Embrace 4 Healthy Habits

High blood lipids impact over 300 million people in China, often silently increasing cardiovascular risk. Learn to avoid common misconceptions and adopt four scientifically backed habits to improve your blood lipid profile and heart health.

Section: CardiologyOct 7, 2025

Intermittent Fasting: Benefits, Risks, and What Recent Research Reveals

Intermittent Fasting: Benefits, Risks, and What Recent Research Reveals

Intermittent fasting has gained popularity for its metabolic and weight-loss benefits, but new research links short eating windows to increased cardiovascular risks, urging caution and personalized approaches.

Section: Family Medicine & NutritionOct 6, 2025

Is More Sleep Better for Cardiovascular Health? Unveiling Risks of Long Sleep Duration and the Protective Role of the Mediterranean Diet

Is More Sleep Better for Cardiovascular Health? Unveiling Risks of Long Sleep Duration and the Protective Role of the Mediterranean Diet

Long sleep duration is linked to increased cardiovascular events in coronary heart disease patients, but adherence to a Mediterranean diet may mitigate these risks, emphasizing sleep’s impact on heart health.

Section: CardiologyOct 6, 2025

Association of Testosterone-Induced Neutrophil and Monocyte Elevation with Thromboembolic Risk: Insights from the TRAVERSE Trial

Association of Testosterone-Induced Neutrophil and Monocyte Elevation with Thromboembolic Risk: Insights from the TRAVERSE Trial

The TRAVERSE trial reveals that testosterone replacement therapy elevates neutrophil and monocyte counts in hypogonadal men, correlating with increased venous thromboembolism and cardiovascular event risk, underscoring the need to monitor t

Section: CardiologyOct 5, 2025

Impact of E-cigarette Use on Cardiovascular Risk, Lung Function, and Clinical Outcomes in Smokers: Insights from a Randomised Placebo-Controlled Trial

Impact of E-cigarette Use on Cardiovascular Risk, Lung Function, and Clinical Outcomes in Smokers: Insights from a Randomised Placebo-Controlled Trial

This review synthesizes trial evidence showing that nicotine-containing e-cigarettes modestly improve lipid profiles but cause no significant changes in lung function or other cardiovascular markers compared to cigarette substitutes in smok

Section: CardiologyOct 5, 2025

Prev 1 2 3 4 Next